What is antibiotic resistance - Ministry of...
Transcript of What is antibiotic resistance - Ministry of...
What is antibiotic resistance?
1
Antimicrobial resistance is the ability of a microbe to
resist the effects of medication that once could
successfully treat the microbe. The term antibiotic
resistance is a subset of AMR, as it applies only to
bacteria becoming resistant to antibiotics.
Advisor:
Pn Nur Shazrina Ahmad
Editor:
Cik Yee Chiou Yann
Co-editor:
Meera Kalaiselvan
Nurain Shafiqah binti
Hassim
In this issue
Antibiotic resistance 1-3
Drug Safety Update 4
Product Brand
Changes
5-6
New Drugs in
Hospital Segamat
7
ADR Cases 8
Medi Kit 9-12
Pharmacy Activities 13-14
PHARMACY BULLETINHOSPITAL SEGAMAT, ISSUE 03/2019
3
COMMUNITY
HOSPITAL
Take antibiotics only as directed by your doctor
Take the whole dose of antibiotics even when you are feeling well
Do not use any previous antibiotics
Do not share antibiotics with others
Prevent infections by regularly washing hands, avoiding close contact
with infected people and regularly taking vaccine doses.
Get culture before starting antibiotics
Antimicrobial prescribing must be reviewed no later than the 72 hours
after it has been initiated
REFERENCES
1) Antibiotic resistance. (2019). Retrieved 8 October 2019, from https://www.who.int/news-room/fact
sheets/detail/antibiotic-resistance
2) What Exactly is Antibiotic Resistance?. (2019). Retrieved 8 October 2019, from
https://www.cdc.gov/drugresistance/about.html
3) WHO releases list of world's most dangerous superbugs. (2019). Retrieved 8 October 2019, from
https://www.statnews.com/2017/02/27/who-list-bacteria-antibiotic-resistance/
4) Newsmax Media, I. (2019). Superbugs List: World Health Organization Names Top 12 Threats. Retrieved 8
October 2019, from https://www.newsmax.com/TheWire/superbugs-list-world-health-
organization/2017/02/27/id/775845/
5) Antimicrobial stewardship - APIC. (2019). Retrieved 8 October 2019, from https://apic.org/Professional-
Practice/Practice-Resources/Antimicrobial-Stewardship/
Disclaimer: While all care is taken to ensure that the information presented in this bulletin is accurate, the board of editors and authors of this bulletin disclaim all
responsibilities for any liability, loss or harm incurred as a result of misinterpretation or inaccuracies within this bulletin. The content of this bulletin is provided for
general informational purposes only and is not intended as, nor should it be considered substitute for professional medical advice.
Deferiprone: Risk of neurological disorders in children
4
Background of Safety Issue
NPRA has received information from Health
Canada regarding a safety alert on the potential
risk of neurological disorders in children receiving
deferiprone at recommended doses.
Previously, the package insert of deferiprone has
already documented this risk occurring in children
who received deferiprone at 2.5 times more than
the recommended dose. However, a safety review
was initiated by Health Canada when two
published cases of neurological disorders
including difficulty walking or difficulty with the
coordination of movement were observed in
children treated with deferiprone at recommended
doses. Health Canada has concluded that these
neurological adverse events may occur with
deferiprone even at recommended doses.
Following this, product manufacturers of
deferiprone are required to update the package
insert with this information.
Upon further investigation, it was noted that the
package insert of deferiprone in Europe was
approved by the European Medicine Agency
(EMA) to be updated with safety information on
the risk of neurological disorders in children
receiving standard doses of deferiprone. Among
the neurological disorders observed with the
standard dose are hypotonia, instability, inability
to walk, and hypertonia with inability of limb
movement. These neurological disorders were
found to gradually subside with discontinuation of
deferiprone.
Adverse Drug Reaction Reports
NPRA has received 351 ADR reports with
721 adverse events suspected to be related
to deferiprone. To date, no report related to
neurological disorders such as difficulty in
walking or difficulty in coordination of
movement has been reported
Advice for Healthcare Professionals
•Monitor for any signs and symptoms of
neurological disorders in patients taking
deferiprone at any dose.
•Please report any adverse events suspected
to be related to deferiprone to NPRA.
Adapted from NPRA Safety Alerts, 12 June 2019
PRODUCT BRAND CHANGES
FOLIC ACID 5MG TABLET
Previous brand: Royce
Manufacturer: ROYCE PHARMA
MANUFACTURING SDN. BHD.
Current brand: Upha Folic
Manufacturer: UPHA
PHARMACEUTICALS MFG
FRUSEMIDE 10 MG/ML INJECTION
Previous brand: Fusix
Manufacturer: SM PHARMACEUTICALS
SDN. BHD.
Current brand: Akoset
Manufacturer: DUOPHARMA (M) SDN.
BHD.
DIOSMIN 450MG AND HESPERIDIN 50MG TABLET
Previous brand: Davmorid
Manufacturer: HOMECARE
Current brand: HemoRid
Manufacturer: UPHA
PHARMACEUTICALS MFG
5
PRODUCT BRAND CHANGES
LOSARTAN 50MG TABLET
Previous brand: Zyltan
Manufacturer: TROIKAA
Current brand: Zylovaa
Manufacturer: XEPA
AMIODARONE 200MG TABLET
Previous brand: Eurythmic
Manufacturer: UNIMED SDN BHD
Current brand: Amiohexal
Manufacturer: IMEKS PHARMA SDN.
BHD.
PROLASE TABLET
Previous brand: Prozyme tab
Manufacturer: ROYCE
Current brand: Noripapain tab
Manufacturer: NORIPHARMA
6
NEWLY APPROVED DRUGS
Tablet Vortioxetine 10mg Tablet Rivaroxaban 20mg
Injection Iron Dextran 50mg Fe/ml Tablet Levodopa 100mg & Carbidopa 25mg
Tablet Empagliflozin 25mg Tablet Amantadine 100mg
7
Adverse Drug Reaction (ADR) Cases In Hospital Segamat
8
2019 ADR Cases by Pharmacological Group
2019 ADR Cases:Cutaneous Reaction
Nutrition & blood disorder 1 %
Anti-Infective 32 %
Ear, Nose and Oropharynx
3%
Supplement 1%Rheumatology 7%
Gastro-intestinal 8%
Endocrine 5%
Analgesic25%
Cardiovascular 18%
1 1
8
1311
17 16
24
11
25
17
9
21
8 8
15 16
8
JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC
2018 : 153, 2019 (Jan-Jun) : 76
2018 2019
Non Cutaneous Cutaneous
Non-cutaneous
32%
Cutaneous 68%
KONVENSYEN INOVASI & KREATIVITI FARMASI (KIKF) 2019
5 - 7 OGOS 2019
Berjaya Waterfront Hotel, Johor Bahru
9
MEDI-KIT, HASIL KUMPULAN MATRIX, HOSPITAL SEGAMAT TELAH
MENDAPAT JOHAN (KATEGORI INOVASI PRODUK) DALAM KIKF 2019
MEDI KIT
Home Medication Review (HMR) merupakan
satu perkhidmatan lawatan ke rumah
pesakit Psikiatrik yang berkonsep
pembekalan Pharmaceutical Care yang
optima kepada pesakit
Masalah-masalah yang dihadapi:
Pendispensan ubat dalam sampul: Ubat
didapati telah dikeluarkan daripada
sampul ubat dan blister asal yang
mengakibatkan kekeliruan pengambilan
ubat.
Pendispensan ubat dalam pillbox:
Pillbox yang digunakan oleh pesakit
hanya dapat menyimpan bekalan ubat
selama 2 minggu dan identiti ubat, tarikh
luput dan kelompok ubat tidak dapat
dikenalpasti.
Objektif Medi-kit:
• Meningkatkan
kepatuhan pesakit
terhadap ubat
• Mengurangkan
kesilapan pengubatan di
kalangan pesakit
• Meningkatkan
produktiviti pegawai
farmasi HMR
10
Inovasi baru untuk memberi ubatkepada pesakit HMR dalam bentuk
album di mana ubat disediakan dalambentuk Unit Dose.
CIRI-CIRI PRODUKBersifat kalis air, tahan lasak dan
boleh digunakan berulang-ulang kali
Ubat tidak perlu dikeluarkan dari
blister asal mengelakkan
masalah ketidakstabilan ubat
Bahan yang digunakan murah,
senang didapati dan boleh
direplikasi di fasiliti lain.
Fleksibiliti berbanding pillbox dari
segi mengubahsuai kekerapan
pengambilan ubat
FAEDAH-FAEDAH
>Penjimatan kos penghantaran ubatapabila kekerapan lawatan dapatdikurangkan & bahan Medi-kit lebihmurah daripada pillbox
>Penjimatan masa pengisian ubat
>Penyediaan pillbox melibatkanpencucian, pengeringan dan pengisian.Penyediaan Medi-kit hanya melibatkanpengisian ubat bentuk UOD sahaja.
>Peningkatan produktiviti PegawaiFarmasi apabila lawatan HMRdikurangkan.
>Nilai tambah kepada pengguna dimana peningkatan kepatuhan pesakitterhadap ubat dan kekerapan pesakitterlupa mengambil ubat telahdikurangkan.
>Patient empowerment di mana Medi-kitmengandungi maklumat pesakit,preskripsi ubat, cara pengambilan ubat,indikasi, nama ubat, durasi.
11
12
Butiran
pesakit
Panduan
Ubat diletakkan
mengikut waktu
pengambilan ubat.
OD, BD, TDS, QID
Preskripsi
Kalender untuk
merekodkan tarikh injeksi
MAJLIS PERPISAHAN PRP
PERTANDINGAN BOWLING
ANJURAN BADAN KEBAJIKAN DAN SOSIAL JABATAN FARMASI
HOSPITAL SEGAMAT
13
PERTANDINGAN BOWLING TELAH DIADAKAN PADA 20 APRIL 2019 DI
BOWLING ALLEY, BANDAR SEBERANG, SEGAMAT. ACARA TERSEBUT
DIMENANGI OLEH UNIT FARMASI LOGISTIK.